All of this disproportionately affects the elderly. In a 2023 study of patients with a median age of 75, approximately 30% of ...
GSK has resubmitted its NDA to the FDA for tebipenem HBr, an oral carbapenem for complicated UTIs, backed by positive phase 3 ...
Mumbai: Wockhardt has announced that it has been informed by the European Medicines Agency (EMA) that WCK 5222, a combination ...
In a significant stride towards advancing treatment options for complicated urinary tract infections (cUTIs), GSK has resubmitted a New Drug Application (NDA) to the FDA for tebipenem pivoxil ...
Urinary tract infections (UTIs) are increasingly common in men, especially with age, posing serious health risks like blood ...
The European Medicines Agency (EMA) has informed Wockhardt that WCK 5222 (combination of Zidebactam 1g + Cefepime 2g) is eligible for Accelerated Assessment, following a pre-submission meeting with ...
Tebipenem HBr is an oral carbapenem antibiotic designed to treat infections that are resistant to standard therapies. Its development is particularly crucial as multi-drug resistant (MDR) bacterial ...
The NDA resubmission is supported by results from the successful Phase 3 PIVOT-PO trial (NCT number – NCT06059846). The trial was stopped early for efficacy in May, 2025 following a planned interim ...
A BMJ review finds tramadol offers minimal chronic pain relief but significantly increases serious side effects, especially ...
A woman's quest for extreme cleanliness led to a dangerous infection. Her routine use of intimate washes stripped away ...
Spero Therapeutics ( ($SPRO) ) has provided an update. On December 19, 2025, Spero Therapeutics reported that its partner GlaxoSmithKline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback